These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20609191)

  • 1. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis.
    Szczeklik W; Nowak I; Seczynska B; Sega A; Krolikowski W; Musial J
    Ther Apher Dial; 2010 Jun; 14(3):354-7. PubMed ID: 20609191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?
    Narita YM; Hirahara K; Mizukawa Y; Kano Y; Shiohara T
    J Dermatol; 2011 Mar; 38(3):236-45. PubMed ID: 21342225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.
    Lissia M; Figus A; Rubino C
    Br J Plast Surg; 2005 Jun; 58(4):504-10. PubMed ID: 15897036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases.
    Koštál M; Bláha M; Lánská M; Koštálová M; Bláha V; Štepánová E; Malý J
    J Clin Apher; 2012; 27(4):215-20. PubMed ID: 22407895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan.
    Yamada H; Takamori K
    Ther Apher Dial; 2008 Oct; 12(5):355-9. PubMed ID: 18937717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxic epidermal necrolysis (Lyell's disease).
    Lissia M; Mulas P; Bulla A; Rubino C
    Burns; 2010 Mar; 36(2):152-63. PubMed ID: 19766401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lyell's syndrome: proposal for a therapeutic protocol].
    Posadinu MA; Sanna E; Canu V; Ciccarese M; Pala PG; Cossu M
    G Ital Nefrol; 2012; 29 Suppl 54():S147-8. PubMed ID: 22388849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis in severe drug-induced toxic epidermal necrolysis.
    Kamanabroo D; Schmitz-Landgraf W; Czarnetzki BM
    Arch Dermatol; 1985 Dec; 121(12):1548-9. PubMed ID: 4062337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients.
    Kim KJ; Lee DP; Suh HS; Lee MW; Choi JH; Moon KC; Koh JK
    Acta Derm Venereol; 2005; 85(6):497-502. PubMed ID: 16396796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic epidermal necrolysis: review of pathogenesis and management.
    Downey A; Jackson C; Harun N; Cooper A
    J Am Acad Dermatol; 2012 Jun; 66(6):995-1003. PubMed ID: 22169256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z
    Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of toxic epidermal necrolysis and related syndromes.
    Mukasa Y; Craven N
    Postgrad Med J; 2008 Feb; 84(988):60-5. PubMed ID: 18322124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis.
    Windle EM
    J Hum Nutr Diet; 2005 Aug; 18(4):311-4. PubMed ID: 16011568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic epidermal necrolysis: does immunoglobulin make a difference?
    Brown KM; Silver GM; Halerz M; Walaszek P; Sandroni A; Gamelli RL
    J Burn Care Rehabil; 2004; 25(1):81-8. PubMed ID: 14726744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of plasmapheresis in the treatment of refractory toxic epidermal necrolysis-like acute cutaneous lupus erythematosus.
    Simsek I; Cinar M; Erdem H; Pay S; Meric C; Dinc A
    Lupus; 2008 Jun; 17(6):605-6. PubMed ID: 18539717
    [No Abstract]   [Full Text] [Related]  

  • 17. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis.
    Quinn AM; Brown K; Bonish BK; Curry J; Gordon KB; Sinacore J; Gamelli R; Nickoloff BJ
    Arch Dermatol; 2005 Jun; 141(6):683-7. PubMed ID: 15967913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of toxic epidermal necrolysis.
    Pirrung MK
    J Intraven Nurs; 2001; 24(2):107-12. PubMed ID: 11836835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected].
    de Sica-Chapman A; Williams G; Soni N; Bunker CB
    Br J Dermatol; 2010 Apr; 162(4):860-5. PubMed ID: 19912214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic epidermal necrolysis with severe hyperbilirubinemia: complete re-epithelialization after bilirubin reduction therapies.
    Kamada N; Yoneyama K; Togawa Y; Suehiro K; Shinkai H; Yokota M; Matsuda K; Oda S; Hirasawa H; Matsue H
    J Dermatol; 2010 Jun; 37(6):534-6. PubMed ID: 20536667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.